Collplant Biotechnologies vs Pmgc Holdings
Collplant Biotechnologies is the larger business, with $2.4m of revenue in fiscal 2025 against $590,084 for Pmgc Holdings (4.0 times as much). Collplant Biotechnologies grew faster (360.4% against -65.5%). Collplant Biotechnologies kept more of each dollar of sales as profit: a net margin of -484.6% against -1313.0%. Collplant Biotechnologies carries less debt relative to equity (0.0% against 18.2%).
| Latest fiscal year | Collplant BiotechnologiesCLGN, 2025 | Pmgc HoldingsELAB, 2025 |
|---|---|---|
| Revenue | $2.4m | $590,084 |
| Revenue growth | 360.4% | -65.5% |
| Net income | −$11.5m | −$7.7m |
| Operating margin | -484.3% | — |
| Net margin | -484.6% | -1313.0% |
| Return on equity | -117.6% | -132.8% |
| Free cash flow | −$9.4m | −$6.4m |
| Cash | $5.6m | $5.4m |
| Total debt | $0 | $1.4m |
| Debt to equity | 0.0% | 18.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 32 |
| Market value | $54.5m | $12.0m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |